Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
First-in-elephant, proof-of-concept vaccination study Study design Study elephants Equivalent to phase I vaccine trial standards, healthy adult elephants rather than EEHV-susceptible calves were chosen for this first-in-elephant proof-of-concept study
TUNEL-positive cells within TLS increased in the sulfasalazine-treated group, while the number of Ki67-positive cells remained unchanged (Figure 5, C and D)
n = 2 per compound)
Sims et al
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
US$ 22.59
US$ 22.19
US$ 24.80
US$ 29.50
US$ 22.54
US$ 21.50
